C
젠큐릭스
229000KOSDAQ47.5 / 100
Reference Date: 2026-10-23
Financial Score18.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Genex develops molecular diagnostic products and services based on liquid biopsy technology, focusing on cancer prognosis and companion diagnostics. Its key products include the breast cancer prognosis test 'GenesWell BCT' and the lung cancer companion diagnostic test 'GenesWell ddEGFR Mutation Test'. The company is also advancing early cancer detection through liquid biopsy products and CTC technology research.
Number of Employees
75people
Average Salary
57.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
2.80Industry Average 1.200.0Point
2.3x industry avg (risky)
ROE
-47.25Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
2.55Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲72.2% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲23.3% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -102.0% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (12%, downtrend)
Current 1,957Won52-week high 5,87052-week low 1,400
1-month return3.0Point
1m 0% (flat)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
4 totalPositive 0Neutral 3Negative 1
- Neutral[기재정정]주요사항보고서(회사합병결정)2026-10-22
- Neutral기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)2026-10-12
- Negative[기재정정]주요사항보고서(영업정지)2026-10-07
- Neutral주요사항보고서(자기전환사채만기전취득결정)2026-09-30